Abstract: Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The dosage form core includes tebipenem pivoxil in free base or salt form, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the dosage form core is from 30:60 to 60:30. The disclosure includes methods of treating bacterial infections including complicated urinary tract infections.

Abstract: The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w/w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w/w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w/w tebipenem pivoxil HBr, 5-25% w/w of a diluent, 0.5 to 5% w/w of a glidant, 0.5 to 5% w/w of a lubricant, and optionally 0.5 to 5% w/w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.

Abstract: The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

Abstract: A method in a client backoff filter. The method includes receiving, from a server, a backoff data packet having backoff metadata. The method also includes saving the backoff metadata in a cache local to the client backoff filter. The method also includes receiving a subsequent request for service. The method also includes checking whether an attribute of the subsequent request for service matches the backoff metadata in the cache. The method also includes performing, responsive to checking, an action including at least one of the group including: blocking, responsive to the attribute matching the backoff metadata in the cache, transmission of the subsequent request for service to a server, and transmitting, responsive to the attribute failing to match the backoff metadata in the cache, the subsequent request for service to the server.

Abstract: Immediate and modified release oral dosage forms of tebipenem pivoxil including dosage form cores are provided. The dosage form core includes tebipenem pivoxil in free base or salt form, and excipients including a binder, a lubricant, optionally a diluent, and optional additional excipients. The weight to weight ratio of tebipenem pivoxil to the excipients in the dosage form core is from 30:60 to 60:30. The disclosure includes methods of treating bacterial infections including complicated urinary tract infections.

Abstract: The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

Abstract: A method in a client backoff filter. The method includes receiving, from a server, a backoff data packet having backoff metadata. The method also includes saving the backoff metadata in a cache local to the client backoff filter. The method also includes receiving a subsequent request for service. The method also includes checking whether an attribute of the subsequent request for service matches the backoff metadata in the cache. The method also includes performing, responsive to checking, an action including at least one of the group including: blocking, responsive to the attribute matching the backoff metadata in the cache, transmission of the subsequent request for service to a server, and transmitting, responsive to the attribute failing to match the backoff metadata in the cache, the subsequent request for service to the server.

Abstract: The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w/w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w/w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w/w tebipenem pivoxil HBr, 5-25% w/w of a diluent, 0.5 to 5% w/w of a glidant, 0.5 to 5% w/w of a lubricant, and optionally 0.5 to 5% w/w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.

Abstract: A method including receiving, from a server, a backoff data packet including first information and second information. The first information includes a backoff command to cease transmitting at least some requests to a service executing on the server, and The second information includes metadata. The method also includes adding the backoff data packet to cached data stored in a cache. The method also includes receiving, from a client, a request data packet including a request for the service. The method also includes comparing request information, associated with the request data packet, to the cached data, including at least comparing the request information to the metadata. The method also includes blocking, responsive to a match between the request information and the cached data, the request data packet from being transmitted to the service.

Abstract: A system configured to: receive a request to generate a dashboard visualization associated with one or more edge devices, the request comprising: a categorization of one or more of the edge devices; and at least one operational descriptor; and in response to the request: obtain, based on the categorization of the one or more edge devices and the operational descriptor, aggregated data associated with the one or more edge devices; determine a status associated with the one or more edge devices for the aggregated data; provide the dashboard visualization to an electronic interface of a computing device, the dashboard visualization comprising the status associated with the one or more edge devices, determine a list of prioritized actions for the one or more edge devices based on the status; and optimize a status of the one or more edge devices based on the determined list of prioritized actions.

Abstract: A method for monitoring performance of one or more a warehouses, including steps to receive a request to generate a dashboard visualization associated with a portfolio of assets, the request comprising: a location of the portfolio of assets; and at least one KPI descriptor; and in response to the request: obtain, based on the location of the portfolio of assets and the KPI descriptor, aggregated data associated with the portfolio of assets; determine metrics associated with the portfolio of as2sets for the aggregated data; and provide the dashboard visualization to an electronic interface of a computing device, the dashboard visualization comprising the metrics associated with the portfolio of assets, and optimize one or more process conditions for one or more assets associated with the portfolio of assets based on the aggregated data.

Abstract: A method comprises storing an ontology for a data store, wherein the ontology comprises a plurality of data object types and a plurality of object property types. The method also comprises storing a validator for a particular object property type of the plurality of object property types, wherein the validator specifies a permitted value for the particular object property type, and storing a parser definition corresponding to the particular object property type, wherein the parser definition specifying a permitted format for the particular object property type. In addition, the method comprises receiving user input that changes a particular data object type of the plurality of data object types, including changing the particular object property type. Finally, the method comprises updating the validator for the particular object property type, and updating the parser definition corresponding to the particular object property type.

Abstract: The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

Abstract: The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

Abstract: In one embodiment, a method comprises creating and storing an ontology for a data store in response to receiving first user input defining the ontology, wherein the ontology comprises a plurality of data object types and a plurality of object property types; creating one or more parser definitions in response to receiving second user input defining the parser definitions, wherein each of the parser definitions specifies one or more sub-definitions of how to transform first input data into modified input data that is compatible with one of the object property types; and storing each of the one or more parser definitions in association with one of the plurality of object property types.

Abstract: System and method for model orchestration and sensor correlation according to certain embodiments. For example, a method includes: accessing a plurality of models, each model of the plurality of models configured to process data; receiving information corresponding to a plurality of sensors associated with a plurality of edge devices; selecting one or more models from the plurality of models based on a processing request; selecting one or more sensors from the plurality of sensors based on the processing request; building one or more model pipelines based at least in part on the one or more selected models and the one or more selected sensors; and deploying the one or more model pipelines.

Abstract: The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w/w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w/w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w/w tebipenem pivoxil HBr, 5-25% w/w of a diluent, 0.5 to 5% w/w of a glidant, 0.5 to 5% w/w of a lubricant, and optionally 0.5 to 5% w/w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.

Abstract: The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

Abstract: In one embodiment, a method comprises creating and storing an ontology for a data store in response to receiving first user input defining the ontology, wherein the ontology comprises a plurality of data object types and a plurality of object property types; creating one or more parser definitions in response to receiving second user input defining the parser definitions, wherein each of the parser definitions specifies one or more sub-definitions of how to transform first input data into modified input data that is compatible with one of the object property types; and storing each of the one or more parser definitions in association with one of the plurality of object property types.

Abstract: The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.